Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Leary

Showing results (201-210 of 217) with videos related to

Pageof 22
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trialJonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2025
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid DisordersDavid Fandrei, Jean Pegliasco, Florence Pasquier, et al.
Nature Medicine|July 1, 2024
Author Correction: Prediction of recurrence risk in endometrial cancer with multimodal deep learningSarah Volinsky-Fremond, Nanda Horeweg, Sonali Andani, et al.
Nature Medicine|May 24, 2024
Prediction of recurrence risk in endometrial cancer with multimodal deep learningSarah Volinsky-Fremond, Nanda Horeweg, Sonali Andani, et al.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 25, 2026
Highlights from the 27th European Congress on Gynecological Oncology in Copenhagen: interview compilation of the ENYGO-IJGC editorial fellowsAndrej Cokan, Martina Aida Angeles, Houssein El Hajj, et al.
Nature Genetics|September 8, 2015
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomasFrancois Le Loarer, Sarah Watson, Gaelle Pierron, et al.
The Lancet. Oncology|May 3, 2024
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trialsFamke C Wakkerman, Jiqing Wu, Hein Putter, et al.
The Lancet. Oncology|December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialElizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
Pageof 22

Showing results (201-210 of 217) with videos related to

Sort By:
Pageof 22
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trialJonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2025
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid DisordersDavid Fandrei, Jean Pegliasco, Florence Pasquier, et al.
Nature Medicine|July 1, 2024
Author Correction: Prediction of recurrence risk in endometrial cancer with multimodal deep learningSarah Volinsky-Fremond, Nanda Horeweg, Sonali Andani, et al.
Nature Medicine|May 24, 2024
Prediction of recurrence risk in endometrial cancer with multimodal deep learningSarah Volinsky-Fremond, Nanda Horeweg, Sonali Andani, et al.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 25, 2026
Highlights from the 27th European Congress on Gynecological Oncology in Copenhagen: interview compilation of the ENYGO-IJGC editorial fellowsAndrej Cokan, Martina Aida Angeles, Houssein El Hajj, et al.
Nature Genetics|September 8, 2015
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomasFrancois Le Loarer, Sarah Watson, Gaelle Pierron, et al.
The Lancet. Oncology|May 3, 2024
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trialsFamke C Wakkerman, Jiqing Wu, Hein Putter, et al.
The Lancet. Oncology|December 3, 2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialElizabeth M Swisher, Kevin K Lin, Amit M Oza, et al.
Pageof 22